Skip to main content

Vitamin D and Calcium Supplementation: An Evidence-Based Update on Fracture and Fall Prevention

July 3, 2026

Vitamin D and Calcium Supplementation: An Evidence-Based Update on Fracture and Fall Prevention

July 3, 2026

Recommendations from Osteoporosis Canada Rapid Response Team.

Authors: Dr. Marie-Josée Bégin, Dr. Claudia Gagnon, Dr. Alan Low, Dr. Shirine Usmani, Dr. Vithika Sivabalasundaram, Dr. Laetitia Michou, Dr. Adrian Lau

Earlier this year, a Canadian systematic review and meta-analysis by Massé and colleagues(1) reported that there were little to no benefits from the use of calcium, vitamin D or combined supplementation for the prevention of fractures and falls.

A total of 69 randomized controlled trials, comprising 153,902 adults aged 18 years or older, met the inclusion criteria of comparing calcium, vitamin D, or combined calcium–vitamin D supplementation versus placebo or no intervention. None of these trials included individuals receiving osteoporosis medications.

On the primary outcome of any fractures, the authors concluded that little to no effect was found from use of calcium supplements (11 trials, 9,067 participants; risk ratio 0.91, 95% confidence intervals 0.81 to 1.01; moderate certainty), vitamin D supplements (36 trials, 92,045 participants; 1.00, 0.95 to 1.06; high certainty), or combined supplementation (15 trials, 51,126 participants; 0.91, 0.84 to 0.99; high certainty).  Calcium, vitamin D, or combined supplementation appeared to have little to no effect on other fracture outcomes and fall risk.

In fact, their analysis demonstrates a statistically significant effect of the combination of vitamin D and calcium on any fractures, including a reduction in hip fractures and non-vertebral fractures (Table 1). However, the authors deemed that these results are not clinically meaningful. The minimal clinically important absolute risk differences between supplementation vs placebo or no treatment were a priori defined thresholds by author consensus, informed by an unstructured review, as 0.7% for hip fracture and 2% for any fracture and non-vertebral fracture.

Their interpretation of minimally important differences is arbitrary, which has important limitations, particularly in the context of relatively safe interventions. We believe these results remain significant and could support interventions aimed at preventing fractures, including serious events such as hip fractures. The observed benefit may have been modest because the study population was at low baseline risk.

Table 1. Summary of findings by Massé et al. on combined vitamin D and calcium supplementation versus placebo or no treatment on fracture risk

Outcomes No. of patients
(No. of trials)
Relative effect
(95% CI)
Absolute risk difference, %
(95% CI)
Certainty of evidence (GRADE)
Risk of any fracture 51,126 (15) RR 0.91
(0.84 to 0.99)
−1.0
(−1.8 to −0.1)
High
Risk of hip fracture 49,909 (9) RR 0.84
(0.74 to 0.96)
−0.3
(−0.5 to −0.1)
High
Risk of non-vertebral fracture 10,324 (7) RR 0.87
(0.78 to 0.96)
−1.6
(−2.7 to −0.5)
Moderate

Several important aspects warrant consideration in the analysis:

  • Of the 69 trials, most were assessed as having high risk of bias.
  • Median follow-up was 2.0 years (1.0-3.2), with 28 trials (41%) having a follow-up ≤1 year. The duration of follow-up was likely insufficient to observe a difference in bone metabolism and fracture risk.
  • Most trials included community dwelling older adults (87%), not at high risk of fractures and falls, sometimes with normal baseline vitamin D levels (27 trials, 39%).
  • The data are not generalizable to people living with osteoporosis or on anti-osteoporosis treatment since they were excluded. It is important to remember that nearly all pivotal studies of anti-osteoporosis therapies included combined vitamin D and calcium supplementation as background therapy.

These results have renewed attention to the role of vitamin D and calcium supplementation in fracture and fall prevention and fuels the concerns of some healthcare professionals and patients. In conversations and interviews with Global News following this publication, the main author provides nuance to the results including(2):

  • “There are still many valid indications for taking calcium and vitamin D, such as taking osteoporosis medication, long-term corticosteroids, certain bone or endocrine diseases, following bariatric surgery, and so on.”
  • “The study is not to encourage people not to take their calcium and vitamin D supplements, but to consult their health-care professional to see if continuing them is still necessary.”
  • This recent meta-analysis does not change the recommendations issued by Osteoporosis Canada in 2023, which is aligned with Health Canada, regarding vitamin D and calcium supplementation(3).
  • For people who meet the recommended dietary allowance for calcium with a variety of calcium-rich foods, we suggest no supplementation to prevent fractures. Health Canada’s recommended dietary allowance for calcium is 1000 mg/d (males aged 51–70 yr) and 1200 mg/d (females > 50 yr and males > 70 yr).
  • Health Canada’s recommended dietary allowance for vitamin D is 600 IU/d (age 51–70 yr) and 800 IU/d (age > 70 yr) for males and females. Given that it is difficult to achieve this level of intake, as few foods contain vitamin D, Health Canada recommends adults older than 50 yr take a vitamin D supplement of 400 IU daily, in addition to consuming vitamin D–rich foods, to achieve the recommended dietary allowance. For people at risk of vitamin D deficiency, additional supplemental vitamin D should be provided.

It is important to remember that the study discussed above does not apply to patients with osteoporosis, previous fragility fractures, on anti-osteoporotic therapies, or those with a condition associated with a high risk of vitamin D deficiency.

Table 2. Risk factors for vitamin D insufficiency/deficiency according to Osteoporosis Canada guidelines(3)

Malabsorption syndromes (e.g. inflammatory bowel disease, celiac disease, bariatric surgery, gastrectomy)
Reduced skin synthesis (e.g. limited sun exposure, increased skin pigmentation)
Liver failure/cirrhosis
Nephrotic syndrome
Chronic kidney disease/renal failure
Medication affecting vitamin D metabolism (e.g. anticonvulsants, glucocorticoids, antiretroviral agents)
Parathyroid disorders (e.g. hypoparathyroidism, hyperparathyroidism)

We strongly encourage dialogue between clinicians and patients on calcium and vitamin D requirements, including assessment of dietary calcium intake, tailored to each patient’s specific needs. Patients are encouraged to seek advice from healthcare professionals regarding vitamin D and calcium supplementation prior to making any changes to their habits.

References

1. Massé O, Mercurio CM, Dupuis S, Al Sahwi M, Arruda A, Dallaire G, et al. Calcium, vitamin D, or combined supplementation to prevent fractures and falls: systematic review and meta-analysis. Bmj. 2026;393:e088050.

2. Fallico A. Vitamin D and calcium may not support bone health as much as thought: study. Global News. 2026 June 4, 2026 1:49 pm.

3. Morin SN, Feldman S, Funnell L, Giangregorio L, Kim S, McDonald-Blumer H, et al. Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Cmaj. 2023;195(39):E1333-e48.

4. Chakhtoura M, Bacha DS, Gharios C, Ajjour S, Assaad M, Jabbour Y, et al. Vitamin D Supplementation and Fractures in Adults: A Systematic Umbrella Review of Meta-Analyses of Controlled Trials. J Clin Endocrinol Metab. 2022;107(3):882-98.

Scientific Advisory Council

Osteoporosis Canada’s rapid response team, made up of members of the Scientific Advisory Council, creates position statements as news breaks regarding osteoporosis. The position statements are used to inform both the healthcare professional and the patient. The Scientific Advisory Council (SAC) is made up of experts in Osteoporosis and bone metabolism and is a volunteer membership.

© Osteoporosis Canada, 2026
Charitable Registration No. 89551 0931 RR 0001